Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.
Verma SS, Bergmeijer TO, Gong L, Reny JL, Lewis JP, Mitchell BD, Alexopoulos D, Aradi D, Altman RB, Bliden K, Bradford Y, Campo G, Chang K, Cleator JH, Déry JP, Dridi NP, Fernandez-Cadenas I, Fontana P, Gawaz M, Geisler T, Gensini GF, Giusti B, Gurbel PA, Hochholzer W, Holmvang L, Kim EY, Kim HS, Marcucci R, Montaner J, Backman JD, Pakyz RE, Roden DM, Schaeffeler E, Schwab M, Shin JG, Siller-Matula JM, Ten Berg JM, Trenk D, Valgimigli M, Wallace J, Wen MS, Kubo M, Lee MTM, Whaley R, Winter S, Klein TE, Shuldiner AR, Ritchie MD; ICPC Investigators. Verma SS, et al. Among authors: dridi np. Clin Pharmacol Ther. 2020 Nov;108(5):1067-1077. doi: 10.1002/cpt.1911. Epub 2020 Jul 9. Clin Pharmacol Ther. 2020. PMID: 32472697 Free PMC article.
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).
Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR; ICPC Investigators. Bergmeijer TO, et al. Among authors: dridi np. Am Heart J. 2018 Apr;198:152-159. doi: 10.1016/j.ahj.2017.12.010. Epub 2017 Dec 17. Am Heart J. 2018. PMID: 29653637 Free PMC article. Review.
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Lewis JP, Backman JD, Reny JL, Bergmeijer TO, Mitchell BD, Ritchie MD, Déry JP, Pakyz RE, Gong L, Ryan K, Kim EY, Aradi D, Fernandez-Cadenas I, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Gawaz M, Bliden KP, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Schwab M, Klein TE, Shuldiner AR; ICPC Investigators. Lewis JP, et al. Among authors: dridi np. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):203-210. doi: 10.1093/ehjcvp/pvz045. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31504375 Free PMC article.
Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
Dridi NP, Johansson PI, Clemmensen P, Stissing T, Radu MD, Qayyum A, Pedersen F, Helqvist S, Saunamäki K, Kelbæk H, Jørgensen E, Engstrøm T, Holmvang L. Dridi NP, et al. Platelets. 2014;25(7):506-12. doi: 10.3109/09537104.2013.845874. Epub 2013 Nov 18. Platelets. 2014. PMID: 24245960 Clinical Trial.
A single center, open, randomized study investigating the clinical safety and the endothelial modulating effects of a prostacyclin analog in combination with eptifibatide in patients having undergone primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction.
Holmvang L, Ostrowski SR, Dridi NP, Johansson P. Holmvang L, et al. Among authors: dridi np. Prostaglandins Other Lipid Mediat. 2012 Dec;99(3-4):87-95. doi: 10.1016/j.prostaglandins.2012.08.002. Epub 2012 Aug 28. Prostaglandins Other Lipid Mediat. 2012. PMID: 22951358 Clinical Trial.
ST peak during percutaneous coronary intervention serves as an early prognostic predictor in patients with ST-segment elevation myocardial.
Lønborg J, Kelbæk H, Engstrøm T, Helqvist S, Kløvgaard L, Holmvang L, Vejlstrup N, Jørgensen E, Saunamäki K, Dridi NP, Kaltoft A, Bøtker HE, Clemmensen P, Terkelsen CJ. Lønborg J, et al. Among authors: dridi np. EuroIntervention. 2014 Aug;10(4):466-74. doi: 10.4244/EIJV10I4A80. EuroIntervention. 2014. PMID: 25138184 Free article.
Hypercoagulation assessed by thromboelastography is neither related to infarct size nor to clinical outcome after primary percutaneous coronary intervention.
Dridi NP, Lønborg JT, Radu MD, Clemmensen P, Engstrøm T, Kelbæk H, Jørgensen E, Helqvist S, Saunamäki K, Christensen TH, Baeres FM, Johansson PI, Holmvang L. Dridi NP, et al. Clin Appl Thromb Hemost. 2014 Nov;20(8):825-31. doi: 10.1177/1076029613485411. Epub 2013 Apr 23. Clin Appl Thromb Hemost. 2014. PMID: 23613040 Free article.
ST peak during primary percutaneous coronary intervention predicts final infarct size, left ventricular function, and clinical outcome.
Lønborg J, Kelbæk H, Holmvang L, Vejlstrup N, Jørgensen E, Helqvist S, Saunamäki K, Dridi NP, Ahtarovski KA, Terkelsen CJ, Bøtker HE, Kim WY, Treiman M, Clemmensen P, Engstrøm T. Lønborg J, et al. Among authors: dridi np. J Electrocardiol. 2012 Nov-Dec;45(6):708-16. doi: 10.1016/j.jelectrocard.2012.06.028. Epub 2012 Jul 24. J Electrocardiol. 2012. PMID: 22832151 Clinical Trial.
15 results